following an abbreviated submission:
talazoparib (Talzenna®) is accepted for use within NHSScotland.
Indication under review: In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
Talazoparib offers an additional treatment choice in the therapeutic class of poly ADP-ribose polymerase inhibitors given in combination with a hormonal agent for this indication.
Another medicine combination within this therapeutic class has been accepted under the end of life and orphan equivalent process for this indication.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice271KB (PDF)
Medicine details
- Medicine name:
- talazoparib (Talzenna)
- SMC ID:
- SMC2753
- Indication:
In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 March 2025